OptiNose, Inc. provided preliminary unaudited earnings guidance for the three-month period ended March 31, 2024. For the period, the company expects to report approximately $14.9 million in net revenue from sales of XHANCE; a loss from operations of approximately $8.1 million; and a net loss of approximately $14.1 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.06 USD | +1.92% | -1.85% | -17.83% |
05-20 | OptiNose, Inc. announced that it has received $4.68 million in funding | CI |
05-14 | Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.83% | 154M | |
+45.82% | 765B | |
+40.95% | 632B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.45% | 248B | |
-0.78% | 219B | |
+11.88% | 216B | |
+5.90% | 164B |
- Stock Market
- Equities
- OPTN Stock
- News OptiNose, Inc.
- OptiNose, Inc. Provides Preliminary Unaudited Earnings Guidance for the Three-Month Period Ended March 31, 2024